BioCatalystWatch
TEVAWorkspace / TEVA / OverviewCompany library
TEVA PHARMACEUTICAL INDUSTRIES LTD logo

TEVA PHARMACEUTICAL INDUSTRIES LTD

TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Website

Price
Market cap
Next catalystExpected Q4 2026TEV-’408 — planned seamless vitiligo Phase 2b/3 · Trial initiationCompany release ↗
Cash

Chart & Events

Candle interval

Core Clinical

TEV-’408

IL-15

PreINDP1P3FilingApproved
Upcoming / outlook

TEV-’408

IL-15

PreINDP1P2FilingApproved
Upcoming / outlook

  • Timing and evidence

Upcoming / outlook

TEV-53408

IL-15

PreINDP1P2P3FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

TEV-53408

IL-15

PreINDP1P2P3FilingApproved
Upcoming / outlook

TEV-’408

IL-15

PreINDP1P2FilingApproved
Upcoming / outlook

  • Timing and evidence

TEV-’408

IL-15

PreINDP1P3FilingApproved
Upcoming / outlook

Other pipelines

TEV-’408

IL-15

PreINDP1P2P3FilingApproved
Upcoming / outlook

TEV-’408

IL-15

PreINDP1P2P3FilingApproved
TEV-’287

PreINDP1P2P3FilingApproved
TEV-56278

PD-1

PreINDP1P2P3FilingApproved
Upcoming / outlook

Upcoming / outlook

Upcoming / outlook

Anti TSLP/IL-13 (TEV-‘325)

TSLP × IL-13

PreINDP2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Partner / License out

TEV-56278

PD-1

PreINDP2P3FilingApproved

VEGF

Approved

PreINDP1P2P3FilingApproved

VEGF

Approved

PreINDP1P2P3FilingApproved

Approved / commercial

IL-12/IL-23 p40 × IL-12 × IL-23

Approved

PreINDP1P2P3FilingApproved

IL-12/IL-23 p40 × IL-12 × IL-23

Approved

PreINDP1P2P3FilingApproved

IL-5

Approved

PreINDP1P2P3FilingApproved

IL-12/IL-23 p40 × IL-12 × IL-23

Approved

PreINDP1P2P3FilingApproved

IL-12/IL-23 p40 × IL-12 × IL-23

Approved

PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
Upcoming / outlook

Upcoming / outlook

History / paused

β-adrenergic receptor

PreINDP1P2P3FilingApproved

Financial position

Short-term investments

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Operating
Investing
Financing

Reported shares and borrowings

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

TEVA PR & News

PR & News

TEVA SEC archive